Released Nov 12, 2024, after the close
10-Q filed Nov 12, 2024, 43 days after period end · 0001628280-24-047284
Q3 2024 · 10-Q
Revenue$89.05M$89.05M +60.6% vs Q3 2023+58.4% vs Q2 2024
Net Income-$56.40M-$56.40M N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$1.08-$1.08 N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$55,204,000N/M
Operating Cash Flowderived-$103,501,000N/M
Free Cash Flowderived-$118,590,000N/M
Margins · derived
Operating margin-62.0%+454.7 pt vs Q3 2023
Net margin-63.3%+483.1 pt vs Q3 2023
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $89.05M | $55.43M | $66.40M | $77.61M |
| Net Income | -$56.40M | -$302.89M | -$670.13M | -$101.88M |
| EPS Diluted | -$1.08 | -$6.21 | -$0.41 | -$0.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ginkgo Bioworks Holdings, Inc. · CIK 1830214 · Engraved from SEC EDGAR